NEW YORK, June 17, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Red Cat Holdings, Inc. (NASDAQ: RCAT) between March 18, 2022 and January 15, 2025, both dates inclusive (the “Class Period”), of the important July 22, 2025 lead plaintiff deadline. SO WHAT: If you purchased Red Cat securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Avis Budget Group, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on June 24, 2025 [1]. Group 1: Class Action Details - Investors who purchased Avis Budget securities between February 16, 2024, and February 10, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - The lead plaintiff must file a motion with the Court by June 24, 2025, to represent other class members in the litigation [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [4]. Group 3: Case Allegations - The lawsuit alleges that during the Class Period, Avis Budget made false and misleading statements regarding its fleet rotation plan, which negatively impacted the value of its vehicles and led to billions in impairment charges [5]. - The claims suggest that Avis Budget's financial results and business prospects were overstated, resulting in investor damages when the true information became public [5].

Core Viewpoint - Rosen Law Firm is reminding purchasers of Ibotta, Inc. securities about a class action lawsuit related to the company's initial public offering and subsequent performance issues, with a lead plaintiff deadline set for June 16, 2025 [1][3]. Group 1: Class Action Details - Investors who purchased Ibotta securities may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting the law firm [3][6]. - The lawsuit claims that Ibotta made false or misleading statements regarding its business operations and financial health, which led to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [4].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased PepGen Inc. securities between March 7, 2024, and March 3, 2025, due to alleged misleading statements regarding the effectiveness and safety of PGN-EDO51 and the CONNECT2 study [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that PepGen made false and misleading statements about PGN-EDO51's effectiveness and safety, the CONNECT2 study's adequacy for FDA approval, and the overstated clinical and commercial prospects of PGN-EDO51 [5]. - Investors who purchased PepGen securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Investors interested in joining the class action can do so by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by August 8, 2025, to represent the class in the lawsuit [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Organon & Co. securities during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The class period for the Organon securities lawsuit is from October 31, 2024, to April 30, 2025, inclusive [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A lead plaintiff must file a motion with the court by July 22, 2025, to represent other class members [2]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions [3]. - Rosen Law Firm has a history of significant settlements, including the largest securities class action settlement against a Chinese company at the time [3]. - The firm has consistently ranked in the top 4 for securities class action settlements since 2013 and recovered hundreds of millions for investors [3]. Group 3: Case Allegations - The lawsuit alleges that Organon's defendants made misleading statements about the company's priorities, particularly regarding capital allocation and dividend payments [4]. - It is claimed that the defendants concealed the importance of debt reduction following the acquisition of Dermavant, leading to a 70% decrease in the regular quarterly dividend [4]. - The lawsuit asserts that investors suffered damages when the true information was revealed [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Avis Budget Group, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on June 24, 2025 [1]. Group 1: Class Action Details - Investors who purchased Avis Budget securities between February 16, 2024, and February 10, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - The lead plaintiff must file a motion with the Court by June 24, 2025, to represent other class members in the litigation [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [4]. Group 3: Case Allegations - The lawsuit alleges that during the Class Period, Avis Budget made false and misleading statements regarding its fleet rotation plan, which negatively impacted the value of its vehicles and led to billions in impairment charges [5]. - The claims suggest that these misstatements resulted in significant financial losses for investors when the true situation was revealed [5].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased PepGen Inc. securities between March 7, 2024, and March 3, 2025, due to alleged misleading statements regarding the effectiveness and safety of PGN-EDO51 and the CONNECT2 study [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that PepGen made false and misleading statements about PGN-EDO51's effectiveness and safety, the CONNECT2 study's adequacy for FDA approval, and the overall clinical and commercial prospects of PGN-EDO51 [5]. - Investors who purchased PepGen securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Investors interested in joining the class action can do so by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by August 8, 2025, to represent the class in the lawsuit [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

NEW YORK, June 10, 2025 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Vestis Corporation (NYSE: VSTS) between May 2, 2024 and May 6, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 8, 2025.So What: If you purchased Vestis securities during the Class Period you may b ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Digimarc Corporation during the specified class period of the upcoming lead plaintiff deadline on July 8, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - The class action lawsuit has been filed against Digimarc Corporation, and investors who purchased securities between May 3, 2024, and February 26, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2]. - To participate in the class action, investors must act by July 8, 2025, to serve as lead plaintiff, representing other class members in the litigation [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3]. Group 3: Case Allegations - The lawsuit alleges that Digimarc made false and misleading statements, including the failure to disclose that a large commercial partner would not renew a significant contract on the same terms, which adversely affected subscription revenue and annual recurring revenue [4]. - The misleading statements led to investor damages when the true details became public [4].

NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of DoubleVerify Holdings, Inc. (NYSE: DV) between November 10, 2023 and February 27, 2025, both dates inclusive (the “Class Period”), of the important July 21, 2025 lead plaintiff deadline. SO WHAT: If you purchased DoubleVerify common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency f ...